Reduced insulin-mediated inhibition of VLDL secretion upon pharmacologic alactivation of the liver X receptor in mice

Journal of Lipid Research

Volumn 50, Issue 7, 2009, Pages 1374-1383

  Grefhorst, Aldo ^a   Parks, Elizabeth J ^b,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein B; De novo lipogenesis; FoxO1; LXR; Microsomal triglyceride transfer protein; Stable isotopes; Sterol regulatory element binding protein 1c; T0901317

Indexed keywords

FATTY ACID; INSULIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; HORMONAL REGULATION; HORMONE ACTION; HYPERINSULINEMIA; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN SECRETION; MALE; METABOLIC ACTIVATION; METABOLIC REGULATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STEATOSIS;

ANIMALS; BLOOD GLUCOSE; GENE EXPRESSION; GLUCOSE CLAMP TECHNIQUE; HYDROCARBONS, FLUORINATED; HYPERINSULINISM; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, INBRED C57BL; ORPHAN NUCLEAR RECEPTORS; PARTICLE SIZE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONAMIDES; TRIGLYCERIDES;

EID: 67650561454     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800505-JLR200     Document Type: Article

References (53)

1. Repa, J. J., and D. J. Mangelsdorf. 2002. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 8: 1243-1248.
2. Repa, J. J., S. D. Turley, J. M. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf. 2000. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 289: 1524-1529.
3. Costet, P., Y. Luo, N. Wang, and A. R. Tall. 2000. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275: 28240-28245.
4. Venkateswaran, A., B. A. Laffitte, S. B. Joseph, P. A. Mak, D. C. Wilpitz, P. A. Edwards, and P. Tontonoz. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA. 97: 12097-12102.
5. Schwartz, K., R. M. Lawn, and D. P. Wade. 2000. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274: 794-802.
6. Lehmann, J. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, J. L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, et al. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272: 3137-3140.
7. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. A. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 93: 693-704.
8. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7604-7609.
9. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptordeficient mice. FEBS Lett. 536: 6-11.
10. Grefhorst, A., B. M. Elzinga, P. J. Voshol, T. Plosch, T. Kok, V. W. Bloks, F. H. van der Sluijs, L. M. Havekes, J. A. Romijn, H. J. Verkade, et al. 2002. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipopoprotein particles. J. Biol. Chem. 277: 34182-34190.
11. Grefhorst, A., T. H. van Dijk, A. Hammer, F. H. van der Sluijs, R. Havinga, L. M. Havekes, J. A. Romijn, P. H. Groot, D. J. Reijngoud, and F. Kuipers. 2005. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am. J. Physiol. Endocrinol. Metab. 289: E829-E838.
12. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, et al. 2000. Role of LXR in control of lipogenesis. Genes Dev. 14: 2831-2838.
13. Repa, J. J., G. Liang, J. Ou, Y. Bashmakov, J. M. A. Lobaccaro, I. Shimomura, B. Shan, M. S. Brown, J. L. Goldstein, and D. J. Mangelsdorf. 2000. Regulation of mouse sterol regulatory elementbinding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14: 2819-2830.
14. Yoshikawa, T., H. Shimano, M. Amemiya-Kudo, N. Yahagi, A. H. Hasty, T. Matsuzaka, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, et al. 2001. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21: 2991-3000.
15. Horton, J. D., I. Shimomura, M. S. Brown, R. E. Hammer, J. L. Goldstein, and H. Shimano. 1998. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Clin. Invest. 101: 2331-2339.
16. Joseph, S. B., B. A. Lafitte, P. H. Patel, M. A. Watson, K. E. Matsukuma, R. Walczak, J. L. Collins, T. F. Osborne, and P. Tontonoz. 2002. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277: 11019-11025.
17. Brown, M. S., J. Ye, R. B. Rawson, and J. L. Goldstein. 2000. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 100: 391-398.
18. Cha, J. Y., and J. J. Repa. 2007. The liver X receptor (LXR) and hepatic lipogenesis: the carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282: 743-751.
19. Ishii, S., K. Iizuka, B. C. Miller, and K. Uyeda. 2004. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. USA. 101: 15597-15602.
20. Iizuka, K., R. K. Bruick, G. Liang, J. D. Horton, and K. Uyeda. 2004. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA. 101: 7281-7286.
21. Gordon, D. A., and H. Jamil. 2000. Progress towards understanding the role ofmicrosomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta. 1486: 72-83.
22. Cao, G., Y. Liang, C. L. Broderick, B. A. Oldham, T. P. Beyer, R. J. Schmidt, Y. Zhang, K. R. Stayrook, C. Suen, K. A. Otto, et al. 2003. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 278: 1131-1136.
23. Laffitte, B. A., L. S. Chao, J. Li, R. Walczak, S. Hummasti, S. B. Joseph, A. Castrillo, D. C. Wilpitz, D. J. Mangelsdorf, J. L. Collins, et al. 2003. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA. 100: 5419-5424.
24. Grefhorst, A., J. Hoekstra, T. G. Derks, D. M. Ouwens, J. F. Baller, R. Havinga, L. M. Havekes, J. A. Romijn, and F. Kuipers. 2005. Acute hepatic steatosis in mice by blocking b-oxidation does not reduce insulin sensitivity of very low density lipoprotein production. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G592-G598.
25. den Boer, M. A., P. J. Voshol, F. Kuipers, J. A. Romijn, and L. M. Havekes. 2006. Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production. Am. J. Physiol. Endocrinol. Metab. 291: E1360-E1364.
26. Fisher, E. A., M. Pan, X. Chen, X. Wu, H. Wang, H. Jamil, J. D. Sparks, and K. J. Williams. 2001. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276: 27855-27863.
27. Wetterau, J. R., M. C. Lin, and H. Jamil. 1997. Microsomal triglyceride transfer protein. Biochim. Biophys. Acta. 1345: 136-150.
28. Hagan, D. L., B. Kienzle, H. Jamil, and N. Hariharan. 1994. Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J. Biol. Chem. 269: 28737-28744.
29. Kamagate, A., S. Qu, G. Perdomo, D. Su, D. H. Kim, S. Slusher, M. Meseck, and H. H. Dong. 2008. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J. Clin. Invest. 118: 2347-2364.
30. Wiegman, C. H., R. H. J. Bandsma, M. Ouwens, F. H. van der Sluijs, R. Havinga, T. Boer, D. J. Reijngoud, J. A. Romijn, and F. Kuipers. 2003. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes. 52: 1081-1089.
31. Minehira, K., S. G. Young, C. J. Villanueva, L. Yetukuri, M. Oresic, M. K. Hellerstein, R. V. Farese, J. D. Horton, F. Preitner, B. Thorens, et al. 2008. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J. Lipid Res. 49: 2038-2044.
32. Adiels, M., J. Westerbacka, A. Soro-Paavonen, A. M. Häkkinen, S. Vehkavaara, M. J. Caslake, C. Packard, S. O. Olofsson, H. Yki-Järvinen, M. R. Taskinen, et al. 2007. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia. 50: 2356-2365.
33. Shimano, H., J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and J. L. Goldstein. 1996. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98: 1575-1584.
34. Liang, G., J. Yang, J. D. Horton, R. E. Hammer, J. L. Goldstein, and M. S. Brown. 2002. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277: 9520-9528.
35. Yang, J., J. L. Goldstein, R. E. Hammer, Y. A. Moon, M. S. Brown, and J. D. Horton. 2001. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc. Natl. Acad. Sci. USA. 98: 13607-13612.
36. Fraser, R. 1970. Size and lipid composition of chylomicrons of different Svedberg units of flotation. J. Lipid Res. 11: 60-65.
37. Harris, W. S., B. E. Hustvedt, E. Hagen, M. H. Green, G. Lu, and C. A. Drevon. 1997. N-3 fatty acids and chylomicron metabolism in the rat. J. Lipid Res. 38: 503-515.
38. Timlin, M. T., and E. J. Parks. 2005. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am. J. Clin. Nutr. 81: 35-42.
39. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1343-1351.
40. Améen, C., U. Edvardsson, A. Ljungberg, L. Asp, P. Åkerblad, A. Tuneld, S. O. Olofsson, D. Linden, and J. Oscarsson. 2005. Activation of peroxisome proliferator-activated receptor a increases the expression and activity of microsomal triglyceride transfer protein in the liver. J. Biol. Chem. 280: 1224-1229.
41. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
42. Engelking, L. J., H. Kuriyama, R. E. Hammer, J. D. Horton, M. S. Brown, J. L. Goldstein, and G. Liang. 2004. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 113: 1168-1175.
43. Plösch, T., T. Kok, V. W. Bloks, M. J. Smit, R. Havinga, G. Chimini, A. K. Groen, and F. Kuipers. 2002. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J. Biol. Chem. 277: 33870-33877.
44. Horton, J. D., Y. Bashmakov, I. Shimomura, and H. Shimano. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA. 95: 5987-5992.
45. Hegarty, B. D., A. Bobard, I. Hainault, P. Ferre, P. Bossard, and F. Foufelle. 2005. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc. Natl. Acad. Sci. USA. 102: 791-796.
46. Fleischmann, M., and P. B. Iynedjian. 2000. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem. J. 349: 13-17.
47. Yabe, D., R. Komuro, G. Liang, J. L. Goldstein, and M. S. Brown. 2003. Liver specific mRNA for insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc. Natl. Acad. Sci. USA. 100: 3155-3160.
48. Yellaturu, C. R., X. Deng, L. M. Cagen, H. G. Wilcox, E. A. Park, R. Raghow, and M. B. Elam. 2005. Posttranslational processing of SREBP-1 in rat hepatocytes is regulated by insulin and cAMP. Biochem. Biophys. Res. Commun. 332: 174-180.
49. Zhang, W., S. Patil, B. Chauhan, S. Guo, D. R. Powell, J. Le, A. Klotsas, R. Matika, X. Xiao, R. Franks, et al. 2006. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281: 10105-10117.
50. Kamei, Y., S. Miura, T. Suganami, F. Akaike, S. Kanai, S. Sugita, A. Katsumata, H. Aburatani, T. G. Unterman, O. Ezaki, et al. 2008. Regulation of SREBP1c gene expression in skeletal muscle: role of retinoid X receptor/liver X receptor and forkhead-O1 transcription factor. Endocrinology. 149: 2293-2305.
51. Angulo, P. 2002. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346: 1221-1231.
52. Kumar, K. S., and P. F. Malet. 2000. Nonalcoholic steatohepatitis. Mayo Clin. Proc. 75: 733-739.
53. Barrows, B. R., and E. J. Parks. 2006. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J. Clin. Endocrinol. Metab. 91: 1446-1452.